Peripheral Neuropathic Pain - Pipeline Review, H2 2016

  • ID: 3946488
  • Report
  • 67 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AnaBios Corporation
  • Chromocell Corporation
  • GW Pharmaceuticals Plc
  • Nektar Therapeutics
  • Phosphagenics Limited
  • Spherium Biomed S.L.
  • MORE
Peripheral Neuropathic Pain - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, provides an overview of the Peripheral Neuropathic Pain (Central Nervous System) pipeline landscape.

Peripheral neuropathic pain is a chronic pain state that usually is accompanied by tissue injury. Causes include alcoholism, diabetes, chemotherapy, infections, surgery and multiple sclerosis. Symptoms include burning pain, tingling and numbness. Treatment includes non-steroidal anti-inflammatory drugs, anticonvulsant and antidepressant drugs.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Peripheral Neuropathic Pain.

Peripheral Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Peripheral Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Neuropathic Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AnaBios Corporation
  • Chromocell Corporation
  • GW Pharmaceuticals Plc
  • Nektar Therapeutics
  • Phosphagenics Limited
  • Spherium Biomed S.L.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Peripheral Neuropathic Pain Overview

Therapeutics Development

Pipeline Products for Peripheral Neuropathic Pain - Overview

Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis

Peripheral Neuropathic Pain - Therapeutics under Development by Companies

Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes

Peripheral Neuropathic Pain - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Peripheral Neuropathic Pain - Products under Development by Companies

Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes

Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development

Achelios Therapeutics, Inc.

AnaBios Corporation

Chromocell Corporation

GW Pharmaceuticals Plc

Nektar Therapeutics

Phosphagenics Limited

Spherium Biomed S.L.

Sunovion Pharmaceuticals Inc.

Yuhan Corporation

Zynerba Pharmaceuticals, Inc.

Peripheral Neuropathic Pain - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AXPN-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-8464 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-2230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ECL-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nabiximols - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-171 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxycodone ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-15001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peripheral Neuropathic Pain - Dormant Projects

Peripheral Neuropathic Pain - Discontinued Products

Peripheral Neuropathic Pain - Product Development Milestones

Featured News & Press Releases

Oct 12, 2016: FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN

Jul 28, 2014: Phosphagenics Provides Update on TPM/Oxycodone patch

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Peripheral Neuropathic Pain, H2 2016

Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Peripheral Neuropathic Pain - Pipeline by Achelios Therapeutics, Inc., H2 2016

Peripheral Neuropathic Pain - Pipeline by AnaBios Corporation, H2 2016

Peripheral Neuropathic Pain - Pipeline by Chromocell Corporation, H2 2016

Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016

Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H2 2016

Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H2 2016

Peripheral Neuropathic Pain - Pipeline by Spherium Biomed S.L., H2 2016

Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016

Peripheral Neuropathic Pain - Pipeline by Yuhan Corporation, H2 2016

Peripheral Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Peripheral Neuropathic Pain - Dormant Projects, H2 2016

Peripheral Neuropathic Pain - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Peripheral Neuropathic Pain, H2 2016

Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Achelios Therapeutics, Inc.
AnaBios Corporation
Chromocell Corporation
GW Pharmaceuticals Plc
Nektar Therapeutics
Phosphagenics Limited
Spherium Biomed S.L.
Sunovion Pharmaceuticals Inc.
Yuhan Corporation
Zynerba Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll